The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...
Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.
Interesting Engineering on MSN11d
New hope for UTI patients as FDA approves first-of-its-kind antibiotic in 30 yearsThe U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...
The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...
The FDA has approved GSK’s Blujepa for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...
Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children ...
The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback